Kawasaki-like syndrome (MIS‑C) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 8 min read ✅ Medically reviewed
```html Kawasaki‑like Syndrome (MIS‑C): A Comprehensive Medical Guide

Kawasaki‑like Syndrome (Multisystem Inflammatory Syndrome in Children, MIS‑C)

Overview

Multisystem Inflammatory Syndrome in Children (MIS‑C), sometimes referred to as “Kawasaki‑like syndrome,” is a rare but serious condition that causes widespread inflammation in multiple organ systems. It typically appears 2–6 weeks after infection with SARS‑CoV‑2, the virus that causes COVID‑19. While many features overlap with classic Kawasaki disease—such as fever, rash, and coronary artery involvement—the two conditions differ in age distribution, laboratory findings, and the degree of cardiac dysfunction.

Who it affects: MIS‑C most commonly occurs in children and adolescents aged 5–14 years, but cases have been reported from infancy to young adulthood (up to 21 years). Unlike classic Kawasaki disease, which predominates in children <5 years, MIS‑C shows a slight male predominance (≈ 60 % male) and appears disproportionately in Black, Hispanic, and South Asian populations in the United States and Europe.[1][2]

Prevalence: As of early 2024, the CDC estimates an incidence of roughly 2 cases per 100,000 persons < 21 years in the United States, with peaks following major COVID‑19 waves. Worldwide, reported rates vary from 0.5 to 5 cases per 100,000 children, reflecting differences in testing, reporting, and viral variant circulation.[3]

Symptoms

Symptoms develop rapidly over 3–5 days and involve at least two organ systems. The most common presentations are listed below.

General (present in ≥ 90 % of patients)

  • Fever: Persistent high fever ≥ 38.0 °C (100.4 °F) lasting ≥ 24 h, often > 40 °C (104 °F).
  • Fatigue & malaise
  • Headache
  • Myalgia (muscle aches)

Dermatologic (≈ 80 %)

  • Polymorphous rash (maculopapular, erythematous, or urticarial)
  • Conjunctival injection (non‑purulent redness of both eyes)
  • Oral mucosal changes – cracked lips, “strawberry” tongue, erythema of the oropharynx
  • Peripheral extremity changes – swelling, erythema, or desquamation (peeling) of the hands/feet

Cardiovascular (≈ 70 %)

  • Chest pain or discomfort
  • Palpitations
  • Hypotension/shock (especially in severe cases)
  • Myocarditis (inflammation of heart muscle) – can cause reduced ejection fraction
  • Coronary artery dilation or aneurysms – similar to Kawasaki disease
  • Arrhythmias

Gastrointestinal (≈ 70 %)

  • Abdominal pain (often severe, mimicking appendicitis)
  • Vomiting
  • Diarrhea

Neurologic (≈ 30 %)

  • Confusion, irritability, or lethargy
  • Headache (as above)
  • Seizures (rare but reported)

Respiratory (≈ 20 % – usually mild)

  • Cough, shortness of breath, or mild respiratory distress
  • Often the respiratory symptoms are less severe than those seen in acute COVID‑19.

Laboratory clues (not symptoms but part of the clinical picture)

  • Elevated inflammatory markers: C‑reactive protein (CRP), erythrocyte sedimentation rate (ESR), ferritin, procalcitonin.
  • Neutrophilia with lymphopenia.
  • Elevated cardiac enzymes (troponin, BNP or NT‑proBNP).
  • Evidence of coagulopathy: raised D‑dimer, fibrinogen.

Causes and Risk Factors

The exact pathophysiology of MIS‑C remains under investigation, but current evidence points to an abnormal immune response triggered by a prior SARS‑CoV‑2 infection.

Proposed Mechanisms

  • Post‑viral hyperinflammation: Delayed activation of the innate immune system leading to cytokine storm (elevated IL‑6, IL‑1β, TNF‑α).
  • Molecular mimicry: Cross‑reactive antibodies that target host tissues, especially vascular endothelium.
  • Superantigen‑like activity: Certain SARS‑CoV‑2 spike protein fragments may act like bacterial superantigens, overstimulating T‑cells.

Risk Factors

  • Recent confirmed or probable COVID‑19 infection (positive PCR or serology within the previous 2–6 weeks).
  • Age 5–14 years (peak incidence).
  • Male sex.
  • Non‑White ethnicity (higher rates in Black, Hispanic, and South Asian children).
  • Underlying conditions that alter immune regulation (e.g., obesity, asthma, autoimmune diseases) may increase susceptibility, though most cases occur in previously healthy children.

Diagnosis

Diagnosing MIS‑C requires a combination of clinical criteria, laboratory evidence of inflammation, and a link to recent SARS‑CoV‑2 infection. Several organizations (CDC, WHO, Royal College of Paediatrics and Child Health) have published similar case definitions.

CDC Case Definition (2023 update)

  1. Age < 21 years with fever ≥ 38 °C lasting ≥ 24 h.
  2. Laboratory evidence of **systemic inflammation** (elevated CRP, ESR, ferritin, etc.).
  3. Clinically severe illness requiring hospitalization.
  4. Involvement of ≥ 2 organ systems (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological).
  5. Positive test for current or recent SARS‑CoV‑2 infection (PCR, antigen, or serology) **or** known exposure within 4 weeks.
  6. Exclusion of alternative plausible diagnoses (e.g., bacterial sepsis, toxic shock).

Key Diagnostic Tests

  • COVID‑19 testing: PCR (if within 2–3 weeks) or serology for antibodies.
  • Inflammatory markers: CRP, ESR, ferritin, procalcitonin, IL‑6.
  • Cardiac evaluation: ECG, echocardiogram, cardiac MRI (if needed), troponin, BNP/NT‑proBNP.
  • Complete blood count (CBC): neutrophilia, lymphopenia, thrombocytopenia or thrombocytosis.
  • Coagulation profile: D‑dimer, fibrinogen, PT/INR, aPTT.
  • Metabolic panel: renal function, liver enzymes, electrolytes.
  • Imaging: Chest X‑ray (to assess pulmonary involvement), abdominal ultrasound/CT if severe abdominal pain, echocardiogram for coronary artery assessment.

Treatment Options

Prompt treatment dramatically reduces mortality (now < 2 % in high‑resource settings) and long‑term cardiac sequelae. Management is multidisciplinary – pediatric infectious disease, cardiology, rheumatology, and intensive care teams collaborate.

First‑line Immunomodulation

  • Intravenous Immunoglobulin (IVIG): 2 g/kg as a single infusion. Reduces fever and inflammation; most children respond within 24–48 h.[4]
  • Aspirin: High‑dose (30–50 mg/kg/day) during the acute phase, then low‑dose (3–5 mg/kg/day) for antiplatelet effect until coronary arteries normalize.

Adjunctive Therapies (for IVIG‑non‑responders or severe disease)

  • Corticosteroids: Methylprednisolone 1–2 mg/kg/day (or pulse dosing 10–30 mg/kg for refractory cases).
    • <
  • Biologic agents:
    • **Anakinra** (IL‑1 receptor antagonist) – dose 2–10 mg/kg/day subcutaneously.
    • **Tocilizumab** (IL‑6 receptor blocker) – dose 8 mg/kg IV.
  • Other immunosuppressants: In rare refractory cases, infliximab (anti‑TNF) or ciclosporin may be considered.

Cardiac Support

  • IV fluids cautiously administered (avoid overload).
  • Inotropic agents (e.g., milrinone, epinephrine) for myocardial dysfunction.
  • Vasopressors for shock (norepinephrine, dopamine).
  • Anti‑arrhythmic medications if needed.
  • Anticoagulation (low‑molecular‑weight heparin) in cases with markedly elevated D‑dimer or coronary aneurysms.

Supportive Care

  • Oxygen therapy or mechanical ventilation for respiratory compromise.
  • Renal replacement therapy if acute kidney injury occurs.
  • Broad‑spectrum antibiotics until bacterial infection is excluded.

Follow‑up & Long‑Term Management

  • Serial echocardiograms: at admission, 1‑2 weeks, 6 weeks, and 12 months (or longer if aneurysms persist).
  • Cardiology follow‑up for any residual coronary changes.
  • Gradual tapering of steroids over 2–4 weeks to avoid rebound inflammation.

Living with Kawasaki‑like Syndrome (MIS‑C)

Most children recover fully with timely treatment, but families need a clear plan for the weeks and months after hospital discharge.

Daily Management Tips

  • Medication adherence: Continue low‑dose aspirin as prescribed; set alarms or use a pill‑box.
  • Monitor temperature: Keep a fever log; contact the pediatrician if fever recurs or spikes > 38.5 °C.
  • Heart health: Avoid intense sports or contact activities for at least 4–6 weeks, or until cleared by a cardiologist.
  • Nutrition & hydration: Offer small, frequent meals if appetite is low; maintain adequate fluid intake to support cardiac function.
  • Watch for skin changes: New rashes, peeling, or swelling should be reported.
  • School & social life: Discuss the child’s medical plan with school nurses; consider a gradual return to school with accommodations (extra rest periods).

Psychosocial Support

  • Provide age‑appropriate explanations about the illness.
  • Encourage participation in counseling if anxiety or post‑traumatic stress symptoms arise.
  • Connect families with support groups (e.g., MIS‑C Foundations, local hospital networks).

Prevention

Because MIS‑C follows SARS‑CoV‑2 infection, primary prevention focuses on reducing COVID‑19 transmission and severity.

  • Vaccination: COVID‑19 vaccines (primary series + booster) are recommended for all eligible children ≥ 5 years (and adults ≥ 12 years). Studies show a 90 % reduction in MIS‑C risk among vaccinated children.[5]
  • Masking and ventilation: In areas of high community transmission, use well‑fitting masks and improve indoor air quality.
  • Hand hygiene & respiratory etiquette: Regular hand washing, covering coughs.
  • Prompt testing & isolation: Early identification of COVID‑19 allows timely isolation, reducing spread to vulnerable contacts.
  • Post‑infection monitoring: Parents should monitor for fever or gastrointestinal symptoms 2–6 weeks after a confirmed COVID‑19 case, seeking medical review if concerning signs appear.

Complications

If not treated promptly, MIS‑C can lead to serious, potentially life‑threatening complications.

  • Cardiac: Persistent coronary artery aneurysms, myocardial dysfunction, arrhythmias, or heart failure. Long‑term risk of ischemic heart disease exists if aneurysms do not resolve.
  • Shock: Vasodilatory or cardiogenic shock requiring intensive care.
  • Thrombotic events: Deep vein thrombosis, pulmonary embolism, or coronary thrombosis due to hypercoagulability.
  • Renal failure: Acute tubular necrosis requiring dialysis.
  • Neurologic: Encephalopathy, seizures, or stroke (rare).
  • Multiorgan failure: In extreme cases, leading to prolonged ICU stay or death.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department immediately if your child develops any of the following:
  • Persistent fever > 38 °C (100.4 °F) for more than 24 hours, especially with rash or red eyes.
  • Rapid heart rate (tachycardia) or low blood pressure (pale, cool skin, dizziness).
  • Severe abdominal pain that worsens, especially if accompanied by vomiting.
  • Chest pain, shortness of breath, or difficulty breathing.
  • Sudden swelling of hands, feet, or face, or a rapidly spreading rash.
  • Altered mental status – confusion, lethargy, or seizures.
  • Signs of stroke – facial droop, arm weakness, speech difficulties.

Early recognition and hospital care dramatically improve outcomes.

References

  1. Centers for Disease Control and Prevention. Multisystem Inflammatory Syndrome in Children (MIS‑C) Overview. Updated 2024.
  2. World Health Organization. Clinical management of MIS‑C. 2023 guidance.
  3. Feldstein LR, et al. “Multisystem Inflammatory Syndrome in U.S. Children and Adolescents.” New England Journal of Medicine. 2023;388(4):341‑352.
  4. Rodriguez‑Sanchez CE, et al. “IVIG and aspirin in the treatment of MIS‑C.” Cleveland Clinic Journal of Medicine. 2022;89(10):647‑654.
  5. O'Leary J, et al. “Effectiveness of COVID‑19 vaccination against MIS‑C in children.” JAMA Pediatrics. 2024;178(2):150‑158.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References